NCT07773155 Pain Control With Ketorolac and Nerve Block After Wrist and Hand Surgery
| NCT ID | NCT07773155 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Chicago |
| Condition | Surgery, Upper Extremity |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-03-17 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 120 participants in total. It began in 2025-03-17 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to learn about the effectiveness of different pain control options after hand and wrist surgery, specifically Ketorolac, Tylenol, and a regional nerve block. Ketorolac (Toradol) is a nonsteroidal anti-inflammatory drug (NSAID) that is similar to ibuprofen (Motrin or Advil). Tylenol (acetaminophen) is a commonly used over the counter drug. A nerve block is pain medication that is applied directly to the nerves around the surgical site before the surgery and keeps working to reduce pain in the area for several hours after the surgery. All of these medicines and procedures are approved by the Food and Drug Administration (FDA) for patient care. This study aims to understand if using these medicines in combination helps patients having hand and wrist surgery avoid the need for opioid pain medications.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older 2. Undergoing upper extremity surgery performed by a hand and upper extremity orthopaedic surgeon at the University of Chicago. 3. Undergoing procedure with regional nerve block Exclusion Criteria: 1. Age less than 18 years 2. Concomitant chronic opioid use 3. Postoperative opioid use (surgery through POD 14) for condition other than repaired fracture 4. Medical contraindication to ketorolac use, including pregnancy 5. Undergoing multiple concurrent surgical procedures 6. Unable to communicate numerical pain score
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07773155 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Surgery, Upper Extremity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07773155 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07773155 currently recruiting?
Yes, NCT07773155 is actively recruiting participants. Contact the research team at jwolf@bsd.uchicago.edu for enrollment information.
Where is the NCT07773155 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07773155 clinical trial?
NCT07773155 is sponsored by University of Chicago. The trial plans to enroll 120 participants.